Dual targeting of BCMA and B7-H3 with CAR T cells and bispecific protein engagers enhances anti-myeloma activity
Dual targeting of BCMA and B7-H3 with CAR T cells and BiPE synergistically enhances T cell activation, effector function, and cytotoxicity against MM. This combinatorial strategy has the potential to overcome resistance mechanisms and represents a promising therapeutic approach for improving outcomes in MM and other BCMA<sup>+</sup>/B7-H3<sup>+</sup> malignancies.
Authors
- Jatuporn Sujjitjoon (ORCID: https://orcid.org/0000-0002-5459-8031)
- Pa‐thai Yenchitsomanus (ORCID: https://orcid.org/0000-0001-9779-5927)
- Pornpimon Yuti (ORCID: https://orcid.org/0000-0002-9121-5079)
- Nunghathai Sawasdee (ORCID: https://orcid.org/0000-0003-1951-9948)
- Seiji Okada (ORCID: https://orcid.org/0000-0003-3124-5206)
- Mutita Junking (ORCID: https://orcid.org/0000-0002-8347-3000)
- Naeramit Sontayananon
Institutions
- Siriraj Hospital (TH)
- Kumamoto University (JP)
Publication Details
- Journal
- Biomedicine & Pharmacotherapy
- Published
- 2025-11-25
- DOI
- https://doi.org/10.1016/j.biopha.2025.118820
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00